加载中
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
前收盘价
US$13.42
+US$0.38 · +2.91%
盘中时间采用ET。市场数据可能有所延迟。
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
日内区间
当前US$13.42
52周区间
当前US$13.42
营业利润
净利润
| 项目（USD） | 2026财年 | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|---|
| 销货成本 | — | — | — | — | 457.5万 USD |
| 毛利 | — | — | — | — | −457.5万 USD |
| 研究与开发 | 2.21亿 USD | 1.89亿 USD | 1.75亿 USD | 1.27亿 USD | 8064.5万 USD |
| 销售、一般及管理费用 | 9873.5万 USD | — | — | — | 3626.4万 USD |
| 营业费用 | 3.2亿 USD | 2.62亿 USD | 2.35亿 USD | 1.77亿 USD | 1.17亿 USD |
| 利息收入 | 1362.5万 USD | 2112万 USD | 2335.6万 USD | 1000.6万 USD | 39万 USD |
| 利息支出 | 885.9万 USD | 789.3万 USD | 666万 USD | 416万 USD | 222.3万 USD |
| 折旧和摊销 | 333.2万 USD | 350.2万 USD | 265.5万 USD | 244.7万 USD | 214.7万 USD |
| 营业利润 | −3.2亿 USD | −2.62亿 USD | −2.35亿 USD | −1.77亿 USD | −1.21亿 USD |
| 净利润 | −3.14亿 USD | −2.47亿 USD | −2.16亿 USD | −1.74亿 USD | −1.18亿 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$18.67
上涨空间 39.12%报告持有此股票敞口的交易所交易基金。
State Street SPDR S&P Biotech ETFXBI3288.15万0.33%98.74亿 USD0.35%US$153.77+3.00%
Vanguard Morningstar Total Stock Market ETFVTI3018.21万0.00%2.3万亿 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM2762.35万0.04%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF1332.72万0.01%954亿 USD0.05%US$235+0.80%
iShares Biotechnology ETFIBB883.84万0.08%108.2亿 USD0.44%US$206.49+3.00%
Vanguard Russell 2000 ETFVTWO695.99万0.04%180亿 USD0.06%US$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA555.22万0.03%218.24亿 USD0.03%US$32.79+0.40%
F/M Emerald Life Sciences Innovation ETFLFSC546.36万4.63%1.18亿 USD0.79%US$42.6071+2.24%State Street SPDR S&P Biotech ETFXBIVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAF/M Emerald Life Sciences Innovation ETFLFSCAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
